After reviewing the sources provided, there is no specific information regarding the use of Lurbinectedin during breastfeeding. The FDA label for Lurbinectedin does not provide any guidance on the use of the drug during lactation [2]. The Oncology Nursing Society (ONS) drug reference sheet for Lurbinectedin also does not mention anything about breastfeeding and Lurbinectedin [3]. The Drug Patent Watch website does not provide any information on Lurbinectedin and breastfeeding [1].

It is important to note that Lurbinectedin is a cytotoxic chemotherapy drug used to treat certain types of cancer, including small cell lung cancer and metastatic triple-negative breast cancer [2]. Due to the potential risks associated with chemotherapy drugs, it is recommended that women who are breastfeeding should not receive chemotherapy treatment [2].

Therefore, it is important for lactating women to consult with their healthcare provider before taking any medications, including Lurbinectedin, to discuss the potential risks and benefits. The healthcare provider can provide the necessary guidance and information to make an informed decision regarding the use of Lurbinectedin during breastfeeding.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://voice.ons.org/news-and-views/oncology-drug-reference-sheet-lurbinectedin